Aprea Therapeutics Inc (APRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2023 | 09-2023 | 06-2023 | 03-2023 | 12-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -14,287 | -10,844 | -7,639 | -4,380 | -112,662 |
| Depreciation Amortization | 7 | 2 | 1 | 0 | 186 |
| Accounts payable and accrued liabilities | 828 | 22 | 290 | -17 | -859 |
| Other Working Capital | 1,619 | 2,082 | 1,199 | 1,370 | -1,759 |
| Other Operating Activity | -344 | 300 | -47 | 47 | 90,082 |
| Operating Cash Flow | $-12,178 | $-8,438 | $-6,196 | $-2,979 | $-25,011 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -93 | -86 | N/A | N/A | N/A |
| Investing Cash Flow | $-93 | $-86 | $0 | $0 | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 5,789 | 5,789 | 5,789 | 5,789 | 683 |
| Other Financing Activity | -649 | -649 | -649 | -649 | 0 |
| Financing Cash Flow | $5,140 | $5,140 | $5,140 | $5,140 | $683 |
| Exchange Rate Effect | -8 | -9 | -5 | 48 | 39 |
| Beginning Cash Position | 28,787 | 28,787 | 28,787 | 28,787 | 53,076 |
| End Cash Position | 21,648 | 25,394 | 27,725 | 30,996 | 28,787 |
| Net Cash Flow | $-7,139 | $-3,393 | $-1,061 | $2,209 | $-24,289 |
| Free Cash Flow | |||||
| Operating Cash Flow | -12,178 | -8,438 | -6,196 | -2,979 | -25,011 |
| Capital Expenditure | -93 | -86 | 0 | 0 | N/A |
| Free Cash Flow | -12,271 | -8,524 | -6,196 | -2,979 | -25,011 |